Pharma Notes

Helix BioPharma Corp.

(Aurora, ON) has commenced patient screening for the sixth dose level cohort in its ongoing Phase 1/2 clinical study of LDOS47 in Poland. This follows completion of the fi rst treatment cycle of the three patients enrolled in the fi fth dose level cohort, in which L-DOS47 therapy was well tolerated as reviewed by the trial steering committee. The study is an open-label study to evaluate the safety, tolerability and preliminary effi cacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC. The study commenced with a starting dose of 0.12 micrograms of L-DOS47 per kilogram of patient body weight in the fi rst patient cohort. Patients to be enrolled in the sixth cohort will receive the next L-DOS47 dose level as planned in the study protocol, which is 0.78 micrograms of L-DOS47 per kilogram of patient body weight.

Qu Biologics Inc.

(Vancouver, BC) has been granted its second broad Australian patent for the targeted treatment of various cancers, including all common cancers. Australian Patent No.2007308721 involves the tissue-targeted activation of the immune response to treat cancers. The patent encompasses formulations of killed viruses to stimulate this site specifi c anti-tumour immune response. Qu Biologics develops immunotherapies called Site Specifi c Immunomodulators (SSIs), which are derived from inactivated bacteria and viruses aimed at stimulating the body’s own immune system against cancer and autoimmune disease. The company’s SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specifi c tissue/organ system.

Sirona Biochem Corp.

(Vancouver, BC) has signed a global exclusive licensing agreement with Obagi Medical Products for the commercialization of its skin lightening compound TFC-849. Sirona Biochem will receive a licensing fee and ongoing royalty payments for global product sales from Obagi Medical Products. As part of the agreement Sirona will transfer its patented skin lightening technology and know-how to Obagi. Obagi will be responsible for the manufacturing, distribution and global sales of the fi nal commercial products. Target launch of products including Sirona Biochem’s TFC-849 is Q4 2014 for Obagi. The exclusive license for TFC849 is valid for the global Valeant Pharmaceuticals family of companies.

Quality Products for Your Lab at Affordable Prices!

SAVE 10%

Millipore Replacement Cartridges/Products Water Filtration Products

*Millipore is used for identification purposes only Cat. No. *Millipore Cat. No. Description

WYV-AMCMCDD02 WYV-AMCCF2203 WYV-AMCMB2202 WYV-AMCOS2201 WYV-AMCPT4001 WYV-AMCPT6001 WYV-AMCQP0101 WYV-AMCPT0101 WYV-AMCHP1001 WYV-AMCFP1001 WYV-AMCPT2001 CFOF01205 REPLACEMENT KIT 4 BOWL Milli-Q System

CDFC02203 Carbon Filters 55 cm (22 in), 3/pk

CPMB02202 Ion-Exchange Cartridge 55 cm (22 in.), 2/pk

CDEX02201 Organic Scavenger Cartridge 55 cm (22 in.), 1/pk PR0GTL0S1US PT-TL1 Long Pretreatment Pack, 1/pk PRPK0L0S1US PT-60 Pre-System Pretreatment Pack, 1/pk CPMQ004R1 High Purity Polishing HP-Pack 1 (RO & Distilled Feed), 1/pk

CPR0P0402 RO Pretreatment PT-Pack, Double Sided, 1/pk QGARD00R1 ULTRA Brand HP Pack R1 (RO & Distilled Feed), 1/pk QTUM000EX ULTRA Brand FP Pack EX, 1/pk

PR0G00002 ULTRA Brand Pretreatment PT-Pack 20, 1/pk Price Special

$479.00 $431.10 $568.00 $511.20 $543.00 $488.70 $318.00 $286.20 $338.00 $304.20 $332.00 $298.80 $441.00 $396.90 $391.00 $351.90 $224.00 $201.60 $270.00 $243.00 $283.00 $254.70

Quality Filters from Wyvern Scientific

Valid until December 31, 2014